The Science of
Self-Optimization

Appetite Suppression

GLP-1 agonists became a cultural phenomenon because they deliver dramatic short-term weight loss. The honest framing is chronic-disease pharmacology — effective while taken, compensation when withdrawn, best used alongside the nutritional foundation the drug amplifies.

Peptide-based appetite suppression splits across four classes — incretin agonists (semaglutide, tirzepatide, retatrutide), amylin analogs (cagrilintide), hypothalamic peptides (BRP), and growth-hormone fragments (AOD-9604). The multi-pathway arms race is producing larger weight losses, the weight-regain-on-discontinuation pattern is producing harder questions, and the nutritional foundation is producing the difference between therapeutic weight loss and iatrogenic frailty.